All posts by Leo Goldstein

Fauci Lied about Cross-Reactivity Study

Dr. Anthony Fauci brazenly lied to Senator Rand Paul, MD, when questioned about preexisting immunity to COVID-19, that some people have from coronavirus common colds. Existence of such cross-reactivity was not in doubt and was acknowledged by Dr. Fauci earlier. But on Wednesday, September 23, Dr. Fauci said “there was a study that recently came out that preexisting immunity to coronaviruses that are common cold do not cross-react with the covid-19”. Continue reading Fauci Lied about Cross-Reactivity Study

NIH Scientists Receive Royalties from Big Pharma

Under 15 U.S. Code § 3710c, federal researchers, whose work was patented and commercialized, receive royalties at the rate of at least 15% of what the US government receives from the licensees, capped at $150,000 per person, per year. NIH and CDC pay their scientists 25% (on amounts over $50,000). These royalties are paid even after the person leaves the government employment and continue after his or her death.

NIH, NIAID, or CDC researcher who contributed to the development of a novel drug or therapy, and was named as one of the inventors on a commercialized patent, may be entitled to $3 million in royalties over the 20-year lifespan of the patent.  Continue reading NIH Scientists Receive Royalties from Big Pharma

COVID-19 Panel Gilead Ties

September 22: H. Clifford Lane, Co-Chair of the Panel, is a co-author of the fraudulent NIAID study of Remdesivir (Beigel et al., May 22), which served the Panel as an excuse to recommend the use of Remdesivir. He has not disclosed co-authorship. Undisclosed ties of two other Co-Chairs (Roy M. Gulick and Henry Masur) to Gilead are listed below.

All other Panel members have been selected by these Co-Chairs, all of whom had ties to Gilead and concealed them!

August 3: they knew that remdesivir was ineffective! but promoted it anyway. Continue reading COVID-19 Panel Gilead Ties

Remdesivir has only insignificant antiviral effect against SARS-COV-2 but dangerous adverse events

version 2, 2020-09-20

Bullet Points
  • In the recommended doses (200 mg on day 1, 100 mg per day after that), Remdesivir (RDV) has only insignificant antiviral effect against SARS-COV-2.
  • RDV treatment in accordance with the current recommendations is likely to significantly increase mortality in severe COVID-19 patients.
  • Only 3 (three) useful clinical trials have been cited by the FDA in the two EUAs they issued for RDV and by the NIH COVID-19 Treatment Panel in its recommendations to use RDV for COVID-19.
  • Only one of the referenced studies claimed clinical benefits of RDV for COVID-19 patients, but it is invalidated by conflicts of interest, misleading reporting of results, suspicious data, and multiple significant changes in the protocol in the middle of the study
  • The lack of RDV’s antiviral effect for SARS-COV-2 is consistent with the results of its trials for respiratory coronavirus on animals.
  • The lack of RDV’s antiviral effect for SARS-COV-2 is also consistent with hindsight interpretation of early in vitro trials. RDV and Chloroquine (CQ) have shown similar selective antiviral effects in vitro. However, in vivo, CQ accumulates in lung tissue, while RDV does not. Even with this accumulation, CQ/HCQ is only effective in a synergetic combination with additional medicines, such as Azithromycin (AZ) and/or Zinc.

Continue reading Remdesivir has only insignificant antiviral effect against SARS-COV-2 but dangerous adverse events

The Myth that HCQ Interferes with RDV

It is increasingly clear that on June 15, the FDA executed two coordinated attacks against Hydroxychloroquine (HCQ). One was the EUA revocation, supported by a junk science memo, and a press release saying “the FDA determined that chloroquine and hydroxychloroquine are unlikely to be effective in treating COVID-19 for the authorized uses in the EUA(emphasis is added). The Big Tech and MSM distorted this already incorrect determination by omitting the last clause.

But within hours of this press release, the FDA issued another attack with a scary title Coronavirus (COVID-19) Update: FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of a COVID-19 Treatment Authorized for Emergency Use. This “update”  started with Continue reading The Myth that HCQ Interferes with RDV

Hydroxychloroquine is Effective and Approved

Hydroxychloroquine (HCQ) is approved by the FDA as an antimalarial and anti-rheumatic medication and can be prescribed by doctors for any disease. Neither the issuance nor the revocation of the Emergency Use Authorization (EUA) for HCQ has any impact on its status as an approved drug available for prescriptions. The EUA was only needed to use HCQ from the Strategic National Stockpile. Continue reading Hydroxychloroquine is Effective and Approved

Yes, there is a cure for COVID-19

The world has a cure for COVID-19. The current COVID-19 mortality in all countries of the Northern Hemisphere, except for Israel, is 4-40 times lower than in the US. Israel stopped using Hydroxychloroquine, probably under the influence of the Big Tech misinformation.

Fig. 1. COVID-19 mortality in the US, Canada, Europe, Asia, Africa, China, and India. Deaths per Million, per day, averaged over 7 days.

Continue reading Yes, there is a cure for COVID-19

The Lancet Doubles Down on anti-HCQ Fraud

2020-08-25 Mehra et al. was worse than fraud.

On August 22, The Lancet published an editorial Trump versus Biden: a fight for the health of a nation, attacking Trump administration and repeating talking points of the Democrat-Socialist party. For example: “The US must move away from a system in which health care is politicised, contentious, and tied to employment, income, and immigration status. In addition, President Trump’s isolationist and anti-scientific adminstration [sic!] has de-prioritised health and health care.” The Lancet is a British journal. This act is an open and in-your-face interference in the American elections.

The British government might re-consider any support it provides to The Lancet. Scientists, regulatory bodies, and the public in both countries should take notice that The Lancet became a political journal, publishing scientific articles matching its politics, and discount them.

On August 21, The Lancet Rheumatology published another anti-HCQ paper, with a surprisingly similar title to the fraudulent  Mehra et al., which was published on May 22 and retracted on June 4.  This new paper is titled: Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. While it  might not be be an outright fraud, it is incorrect and produced by dubious methods. Continue reading The Lancet Doubles Down on anti-HCQ Fraud

A Study of Actual HCQ Usage is Published in WUWT

Hydroxychloroquine in COVID-19 Treatment, Actual Usage in the USA is published in WUWT. The Supplementary Materials:

Summary.xlsx

Hydroxychloroquine-Actual-Use-USA-Attachment.zip

Based on its results, roughly about 500 thousands Americans were prescribed Hydroxychloroquine for COVID-19 treatment from January through the end of July.

If Hydroxychloroquine were 1/100th as dangerous as fake scientists claim, the media would be choke full of stories about naive citizens, that died from the “Trump touted drug”. Instead, the media regurgitates the story from March 23, when a man died from ingesting fish tank cleaner with chloroquine phosphate. The police suspected that was a murder, but decided to call it an incident.

Same day correction: the rough estimate is changed to ~500,000.

2020-08-25: The Supplementary Materials are uploaded

IDSA against HCQ and Plasma

Two days ago, the Infectious Disease Society (IDSA) published its recommendations against the use of Hydroxychloroquine and convalescent plasma for the treatment of COVID-19. Apparently, they knew that Trump would announce the FDA authorization of plasma therapy for COVID-19, and they wanted to strike  preemptively. At the same time, they recommended the use of the ineffective and unsafe drug, Remdesivir. Continue reading IDSA against HCQ and Plasma

Convalescent Plasma is OK, but Hydroxychloroquine is Better

Convalescent plasma has been widely and successfully used as a COVID-19 treatment. For example, a survey Sermo W3, April 15, shows that 46% of the doctors that had used convalescent plasma or had seen it used, said it is very or extremely effective against COVID-19.

Plasma has been positively mentioned in Hydroxychloroquine-based COVID-19 Treatment, A Systematic Review of Clinical Evidence and Expert Opinion from Physicians’ Surveys.

Continue reading Convalescent Plasma is OK, but Hydroxychloroquine is Better

Oseltamivir and QT Interval

The Brazilian trial, Borba et al. [3], in which critically ill patients were given toxic doses of chloroquine (not hydroxychloroquine), also included oseltamivir. Oseltamivir (Tamiflu®) is known to prolong QT interval [1]. It is also known to cause Bradycardia, both confirmed by animal experiments [2] (citing [1] for the results in humans). The NIH COVID-19 Treatment Guidelines described the Brazilian HCQ trial in detail, but failed to mention that oseltamivir is known to prolong QT interval on its own. The NIH Guidelines also failed to mention that the study authors stressed that the findings cannot be extrapolated to non-severe cases (emphasis is mine): Continue reading Oseltamivir and QT Interval

Multiple Causes of Increase in C19 Cases & Hospitalizations

Update 2020-08-12. A push for more testing might have caused increase in the COVID-19 infection cases, hospitalizations, and deaths. Some doctors require patients with COVID-19 symptoms to have a PCR test before prescribing HCQ-based treatment. More testing caused longer processing times. Consequently, many COVID-19 patients could not receive Hydroxychloroquine-based treatment in time. Some of them ended up in hospitals or even worse. Even patients, who got over it without visible consequences, carried a higher viral load for longer time and spread it wider, compared with those who received HCQ treatment immediately  or after a short wait. Thus, excessive testing was harmful.

The testing numbers were increasing all the time. In the end of June, a push to suddenly increase the demand for PCR tests started, possibly under influence of somebody attempting to overwhelm the existing testing capacities. Continue reading Multiple Causes of Increase in C19 Cases & Hospitalizations

General Masking is Useless

The author has shown that wearing face masks by the public outside of hospital/nursing settings is useless as source control for COVID-19. When mandated, it becomes harmful [1].

Other research has also shown that wearing masks by the public in general is not effective against the spread of a respiratory illness epidemic [2]: “During the 2009 pandemic of H1N1 influenza (swine flu), encouraging the public to wash their hands reduced the incidence of infection significantly whereas wearing facemasks did notContinue reading General Masking is Useless